AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers

These press releases are for business and financial media.

- 01 March 2000
- ATACAND® PLUS HYPERTENSION TREATMENT GAINS EU APPROVAL AstraZeneca today announced that its new hypertension treatment Atacand® Plus has gained EU mutual recognition in 12 countries.
- 28 February 2000
- ASTRAZENECA FILES SUPPLEMENTAL NEW DRUG APPLICATION WITH FDA FOR 'CASODEX' 150MG MONOTHERAPY FOR THE TREATMENT OF PROSTATE CANCER AstraZeneca today announced that a supplemental new drug application (sNDA) has been filed with the US Food and Drug Administration (FDA) for 'Casodex' 150mg monotherapy for the treatment of locally advanced, non-metastatic prostate cancer.
- 24 February 2000
- FULL YEAR RESULTS 1999 Commentary (81k PDF file) and Figures (184k PDF file)
- 01 February 2000
- ASTRAZENECA WELCOMES GERMAN SUPREME COURT DECISION TO REFER OMEPRAZOLE SPC CASE TO EUROPEAN COURT OF JUSTICE AstraZeneca today welcomed a decision by the German Supreme Court to refer a number of questions about the company's Supplementary Protection Certificate (SPC) for omeprazole to the European Court of Justice (ECJ).
- 04 January 2000
- ASTRAZENECA's OXIS® TURBUHALER® GAINS EUROPEAN UNION APPROVAL FOR 'AS NEEDED' TREATMENT AstraZeneca PLC announced today that Oxis Turbuhaler® (formoterol) has been approved in the European Union (EU) for 'as needed' treatment of asthma symptoms in addition to normal maintenance treatment.

At 21-Nov-2009 09:24 GMT

We continue to communicate openly on a range of issues, including:

Astrazeneca Worldwide